Thousand Oaks, CA, United States of America

Murielle Marie Ellison

This inventor holds 14 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Amgen Inc., Other. Active years: 2011-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Murielle Marie Ellison. Retrieved from https://idiyas.com/inventor/murielle-marie-ellison

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 6)

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 8.0

ph-index = 8

Forward Citations = 394(Granted Patents)

Company Filing History:

13 out of 2,072

Amgen Inc.

patents

1 out of 834,513

Other

patents

Years Active: 2011-2023

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11840558 - Methods of treating non-alcoholic steatohepatitis using FGF21 mutants (2023-12-12),

2. 11072640 - Methods of treating non-alcoholic steatohepatitis using FGF21 mutants (2021-07-27),

3. 10011642 - Methods of treating of diabetes and obesity using FGF21 mutants (2018-07-03),

4. 9493530 - FGF21 mutants comprising a mutation at position 98, 171 and/or 180 (2016-11-15),

5. 9279013 - FGF-21 mutants comprising polyethylene glycol and uses thereof (2016-03-08),

6. 9273106 - FGF mutants with reduced proteolysis and aggregation (2016-03-01),

7. 8835385 - FGF21 polypeptides comprising two or more mutations and uses thereof (2014-09-16),

8. 8795985 - FGF 21 polypeptides comprising two or more mutations and uses thereof (2014-08-05),

9. 8642546 - FGF21 mutant fusion polypeptides and uses thereof (2014-02-04),

10. 8618053 - FGF21 mutants multimers and uses thereof (2013-12-31),

11. 8410051 - FGF21 mutants and uses thereof (2013-04-02),

12. 8361963 - Uses of FGF21 polypeptides comprising two or more mutations (2013-01-29),

13. 8188040 - FGF21 mutants and uses thereof (2012-05-29),

14. 8034770 - FGF21 polypeptides comprising two or more mutations (2011-10-11),

Title: Innovator Spotlight: Murielle Marie Ellison

Introduction: Murielle Marie Ellison is a notable inventor based in Thousand Oaks, California, recognized for her significant contributions to the field of biotechnology. With 14 patents to her name, her work focuses on innovative methods for treating metabolic disorders, aiming to improve health outcomes for patients worldwide.

Latest Patents: Among her latest inventions are groundbreaking patents titled "Methods of treating non-alcoholic steatohepatitis using FGF21 mutants." This invention provides a robust approach that includes nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides themselves, and pharmaceutical compositions that utilize these components. Her inventions notably advance the treatment of non-alcoholic steatohepatitis (NASH) through the employment of FGF21 mutant polypeptides, showcasing her commitment to addressing pressing health concerns.

Career Highlights: Throughout her career, Murielle has worked with notable companies, including Amgen Inc. Her work in the biopharmaceutical sector is characterized by her innovative spirit and dedication to research that leads to tangible advancements in medical treatments.

Collaborations: Murielle has collaborated with esteemed colleagues such as Edward John Belouski and Randy Ira Hecht, combining their expertise to push the boundaries of what's possible in biotechnology. These collaborations have been vital in developing and refining her patented inventions.

Conclusion: Murielle Marie Ellison stands out as a pioneering inventor whose contributions significantly impact the field of biotechnology. Through her innovative patents and collaborative efforts, she continues to lead the way in the advancement of medical treatments for metabolic disorders. Her work exemplifies the spirit of innovation that drives progress in science and healthcare.

Profile summary based on public USPTO records.